Natera, Inc. (NTRA) Down 6.3% — Is It Worth Holding Any Longer?
Natera, Inc. (NTRA) retreated sharply, falling 6.30% to $183.80 on the NASDAQ and giving up $12.35 from its prior close of $196.15. The decline extends a pattern of surrendering ground whenever momentum fades, keeping the stock under persistent pressure despite a recent rebound attempt. Even after this retreat, NTRA remains within its 52-week range of $125.38 to $256.36, though the near-term tone has grown decidedly more defensive as sellers reassert control.
Trading activity was notably subdued for a session of this magnitude, with just 597,846 shares changing hands against a 90-day average of 1,260,887. The lighter-than-usual volume suggests the drop played out without the broad, high-conviction participation that often marks a definitive capitulation — yet the price action still signals a market leaning cautious. The stock now sits roughly 28% below its 52-week high of $256.36, reached on 01/07/2026, a sobering reminder of how much ground has been lost from the peak and how stiff the headwinds facing the shares remain.
Trading across the broader Health Care sector has been similarly uneven, with laggards such as Roivant Sciences (ROIV), Moderna (MRNA), and BioNTech (BNTX) all contributing to a choppy tape. Against that unsettled backdrop, NTRA's single-day loss stands out for its size and reinforces the sense that risk appetite for the space remains fragile.
Why Natera, Inc. Price is Moving Lower
Natera, Inc. (NTRA) has come under renewed selling pressure this week, with the pullback driven more by trading dynamics and investor caution than by any fresh company-specific catalyst. After pushing higher earlier in the week, shares slipped to $191.64 on March 27 on relatively light volume of 140,447 shares, hovering near a closely watched support level around $190.46. That decline followed a March 25 move up to $197.37 on heavier volume — a pattern that frequently signals short-term profit-taking after a bounce, particularly when the broader performance backdrop has been uneven, including a notable slide over the past three months.
Insider activity is adding to the pressure on sentiment. Co-founder Jonathan Sheena sold 4,570 shares between March 18 and March 20 at prices ranging from roughly $196 to $201 under pre-arranged 10b5-1 plans. While he retained a meaningful stake, insider selling near recent highs can create an overhang for momentum-oriented investors and amplify near-term volatility. On the fundamental side, revenue momentum remains solid — the latest quarterly figure came in at $665.5 million, up 12.4% sequentially and approximately 39.8% year over year — but the market appears more preoccupied with profitability, and a -9.02% profit margin continues to fuel skepticism about how quickly that top-line strength can translate into durable earnings.
Analyst sentiment has tilted bullish since the late-February earnings report, with several price target increases following an EPS beat and strong top-line growth. Even so, the stock's February pullback despite those results highlights the central challenge: expectations are elevated, and lingering concerns around margins and the path to profitability can keep shares under pressure even when positive clinical validation headlines emerge.
What is the Natera, Inc. Rating - Should I Sell?
Weiss Ratings assigns NTRA a D rating, with a current recommendation of Sell. Natera was upgraded on 12/26/2023, yet the overall rating remains negative; Weiss Ratings weighs risk-adjusted outcomes rather than operational momentum alone, and shareholders have not been consistently shielded from the downside that accompanies a D-rated profile.
On the reward side, the Good Growth Index reflects revenue growth of 39.79%, and the Good Total Return Index captures periods of favorable performance. Those positives, however, have yet to produce durable profitability or reliable shareholder outcomes. A profit margin of -9.02% keeps the business in the red, and a forward P/E of -128.72 underscores that earnings expectations remain deeply challenged. Put simply, growth alone has not been sufficient to close the performance and quality gaps that underpin the overall D (Sell) rating.
The most significant internal red flag is the Very Weak Efficiency Index, which points to poor effectiveness in converting resources into returns. That matters because operational inefficiency tends to magnify execution risk — especially when conditions tighten or growth decelerates. The Fair Volatility Index similarly implies an uneven trading profile in which drawdowns can materialize quickly and erode the benefit of any upside runs.
Within Health Care sector, Natera sits alongside lower-rated peers such as Roivant Sciences Ltd. (ROIV, D), Moderna, Inc. (MRNA, D-), and BioNTech SE (BNTX, D-). The Excellent Solvency Index offers some balance-sheet reassurance, but it has not been enough to offset weak efficiency and persistent losses — the key factors behind the continued cautionary stance.
About Natera, Inc.
Natera, Inc. (NTRA) is a Health Care diagnostics company operating within the Pharmaceuticals, Biotechnology and Life Sciences industry, with a core focus on molecular testing services. Its business revolves around genetic and genomic assays ordered by clinicians and delivered through a combination of direct sales and laboratory distribution partnerships. Natera supports provider ordering and workflow through its NateraCore platform, alongside phlebotomy and EMR integration services — tools designed to reduce friction for clinicians while managing the operational complexity inherent in regulated clinical testing.
The company's oncology portfolio includes Signatera, a personalized circulating tumor DNA (ctDNA) blood test used for minimal residual disease (MRD) assessment, recurrence monitoring, and treatment response evaluation in previously diagnosed cancer patients. It also offers Latitude, a blood-based MRD test for colorectal cancer, and Altera, a tissue-based comprehensive genomic profiling test. In hereditary cancer screening, Natera markets Empower. These products place the company squarely in crowded, rapidly evolving segments where tests compete on clinical evidence, provider adoption, and seamless integration into care pathways.
In women's health, Natera offers Panorama for non-invasive prenatal testing and Horizon for carrier screening, along with single-gene NIPT options including Fetal Focus and Vistara. Additional products include Anora for miscarriage tissue analysis, Prospera for active rejection assessment in solid organ transplants, and Renasight, a comprehensive kidney gene panel. The company also licenses Constellation, a cloud-based distribution model, and maintains a partnership with BGI Genomics to develop and commercialize next-generation sequencing assays. Founded in 2003, Natera is headquartered in Austin, Texas.
Investor Outlook
Carrying a Weiss Rating of D (Sell), Natera, Inc. (NTRA) occupies a weaker risk/reward tier, making it worth monitoring whether recent momentum can hold above nearby support and reclaim prior resistance levels without triggering renewed volatility. Within Health Care, investors should watch for shifts in risk appetite and any meaningful signs that profitability, cash discipline, or balance-sheet resilience are improving enough to offset the rating's cautionary signal. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--